Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find
out how well it works to prevent cancer from coming back in people who have had a solid tumor
surgically removed, but still have tumor cells in their blood. During the study, the
participant will receive either the study drug or a placebo for as long as 12 months, or
until the cancer comes back, or the side effects of the treatment become too severe.